AccessibilityHelpAbout Us
InVitro International logo

InVitro International(OTC) IVRO

Market Cap$1.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-98%
5 Year-59%
1 Year+9%
1 Month+26%
$0.07
-7.00%
-0.00Today
InVitro International last closing stock price
MetricPriceDate
Last closeUSD 0.072026-09-10
InVitro International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.99%USD 0.072026-09-02
1 month+26.41%USD 0.052026-08-11
3 month-23.95%USD 0.092026-06-12
Year to date-27.67%USD 0.092025-12-30
1 year+8.5%USD 0.062025-09-10
3 year+5.85%USD 0.062023-09-05
5 year-59.31%USD 0.162021-09-10
Since inception-97.74%USD 2.881992-05-01

InVitro International Financials at a Glance

Market Cap

$1.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$771.06K

Net Income (TTM)

$63.06K

EPS (TTM)

$0.00

P/E Ratio

23.25

Dividend

$0.00

Beta (Volatility)

0.06 (Low)

Price

$0.07

Volume

2,000

Open

$0.07

Previous Close

$0.07

Daily Range

$0.07 - $0.07

52-Week Range

$0.03 - $0.16

Estimated Earnings Date

N/A

IVRO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InVitro International

InVitro International is a specialized company focused on developing and supplying non-animal testing kits for various industries. Established in 1985 and based in Placentia, California, the company offers innovative solutions for assessing eye and skin irritation, as well as chemical corrosiveness.

Products and Services
  • Irritection Assay System for irritation testing
  • Corrositex for evaluating chemical corrosiveness
  • Tailored technological support and independent laboratory services
Growth Outlook
  • Revenue increased to $177,760 in Q3 2026, showing resilience
  • Gross profit margin remains strong at 82.1% in Q3 2026
  • Current ratio of 11.56 indicates robust liquidity position
Financial Highlights
  • Net income of $8,474 in Q3 2026, reflecting operational efficiency
  • Trailing twelve months (TTM) P/E ratio stands at 18.6, indicating growth potential
  • Cash and cash equivalents reached $1,225,564 in Q3 2026, ensuring financial stability
InVitro International operates in the medical diagnostics and research sector, providing essential tools for manufacturers across various industries, including cosmetics and pharmaceuticals. The company's flagship products, the Irritection Assay System and Corrositex, are designed to meet the growing demand for non-animal testing methods, aligning with global trends towards ethical testing practices. The growth outlook appears promising, with recent revenue figures indicating a steady increase, alongside a strong gross profit margin. The company's liquidity is notably robust, as evidenced by a current ratio significantly above 1, which suggests a strong ability to cover short-term liabilities. Financially, InVitro International has demonstrated operational efficiency, with a positive net income reported in the latest quarter. The P/E ratio indicates that the company is positioned for potential growth, while the substantial cash reserves provide a cushion for future investments and operational needs. Overall, InVitro International presents a compelling opportunity for investors interested in the evolving landscape of medical diagnostics and ethical testing solutions.
AI Generated • Sep 11, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

5

CEO

W. Richard Ulmer

Website

www.invitrointl.com

Headquarters

Placentia, CA 92870, US

IVRO Financials

Key Financial Metrics (TTM)

Gross Margin

81.88%

Operating Margin

4.45%

Net Income Margin

8.18%

Return on Equity

3.76%

Return on Capital

4.48%

Return on Assets

3.16%

Earnings Yield

4.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.16M

Volume

2.00K

Avg. Volume

8.36K

Financials (TTM)

Gross Profit

$631.35K

Operating Income

$34.34K

EBITDA

$53.30K

Operating Cash Flow

$4.07K

Capital Expenditure

-$4.18K

Free Cash Flow

-$110.00

Cash & ST Invst.

$1.23M

Total Debt

$240.30K

InVitro International Performance Analysis

InVitro International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30USD 853,511-14.9%
20232023-09-30USD 792,628-7.1%
20242024-09-30USD 811,2902.4%
20252025-09-30USD 878,9378.3%
InVitro International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-30-13.0%
Q12025-12-31-10.4%
Q22026-03-3113.3%
Q32026-06-30-14.1%
InVitro International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30USD 0.00-78.6%
20232023-09-30USD 0.00-88.9%
20242024-09-30USD 0.004400.0%
20252025-09-30USD 0.0117.8%
InVitro International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-30-40.0%
Q12025-12-31-58.3%
Q22026-03-3160.0%
Q32026-06-3025.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$177.76K

-24.2%

Gross Profit

$145.95K

-24.0%

Gross Margin

82.10%

N/A

Market Cap

$1.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$288.52K

N/A

Employees

5

N/A

Net Income

$8.47K

-81.7%

EBITDA

$3.62K

-92.4%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$1.23M

-3.1%

Total Debt

$240.30K

-20.2%

Accounts Receivable

$74.53K

+20.4%

Inventory

$179.14K

-6.6%

Long Term Debt

$170.71K

-29.0%

Short Term Debt

$69.59K

+14.5%

Return on Assets

3.16%

N/A

Return on Invested Capital

1.84%

N/A

Free Cash Flow

$6.22K

-65.6%

Operating Cash Flow

$7.32K

-59.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SHMNSOHM, Inc.
$0.00-12.50%
YBGJYubo International Biotech Limited
$0.01+0.00%
MITIMitesco, Inc.
$0.04+0.00%
PLSHPanacea Life Sciences Holdings, Inc.
$0.10+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$78.62-0.00%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.74+0.08%
TNONTenon Medical
$5.30+1.17%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$115.76-0.08%

Questions About IVRO

What is the current price of InVitro International?

InVitro International is trading at $0.07 per share.

What is the 52-week range for InVitro International?

Over the past 52 weeks, InVitro International has traded between $0.03 and $0.16.

How much debt does InVitro International have?

As of the most recent reporting period, InVitro International reported total debt of $240.30K.

How much cash does InVitro International have on hand?

InVitro International reported $1.23M in cash and cash equivalents in its most recent financial results.

What is InVitro International’s dividend yield?

InVitro International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services